Filtered By:
Condition: Ischemic Stroke
Cancer: Cancer
This page shows you your search results in order of relevance. This is page number 19.
Order by Relevance | Date
Total 1713 results found since Jan 2013.
The Effect of Histone Deacetylase Inhibitors Panobinostat or Entinostat on Motor Recovery in Mice After Ischemic Stroke
AbstractUsing rigorous and clinically relevant experimental design and analysis standards, in this study, we investigated the potential of histone deacetylase (HDAC) inhibitors panobinostat and entinostat to enhance recovery of motor function after photothrombotic stroke in male mice. Panobinostat, a pan-HDAC inhibitor, is a FDA-approved drug for certain cancers, whereas entinostat is a class-I HDAC inhibitor in late stage of clinical investigation. The drugs were administered every other day (panobinostat —3 or 10 mg/kg; entinostat—1.7 or 5 mg/kg) starting from day 5 to 15 after stroke. To imitate the current standa...
Source: NeuroMolecular Medicine - December 1, 2021 Category: Neurology Source Type: research
Novel contact-kinin inhibitor sylvestin targets thromboinflammation and ameliorates ischemic stroke
Cell Mol Life Sci. 2022 Apr 13;79(5):240. doi: 10.1007/s00018-022-04257-7.ABSTRACTIschemic stroke is a leading cause of death and disability worldwide. Increasing evidence indicates that ischemic stroke is a thromboinflammatory disease in which the contact-kinin pathway has a central role by activating pro-coagulant and pro-inflammatory processes. The blocking of distinct members of the contact-kinin pathway is a promising strategy to control ischemic stroke. Here, a plasma kallikrein and active FXII (FXIIa) inhibitor (sylvestin, contained 43 amino acids, with a molecular weight of 4790.4 Da) was first identified from fore...
Source: Cancer Control - April 13, 2022 Category: Cancer & Oncology Authors: Zhiye Zhang Chuanbin Shen Mingqian Fang Yajun Han Chengbo Long Weihui Liu Min Yang Ming Liu Dengdeng Zhang Qiqi Cao Xue Chen Yaqun Fang Qiumin Lu Zongliu Hou Yaxiong Li Zhenze Liu Xi Lei Heyu Ni Ren Lai Source Type: research
β-Actin: An Emerging Biomarker in Ischemic Stroke
We examined human and preclinical studies to gain a comprehensive understanding of the literature on the subject. Most relevant literatures focus on preclinical research, and pay more attention to the role of β-actin in the process of cerebral ischemia, but some recent literatures reported that in human studies, serum β-actin increased significantly in the early stage of acute cerebral ischemia. This review will investigate the basic biology of β-actin, pay attention to the potential role of serum β-actin as an early diagnostic blood biomarker of ischemic stroke, and explore its potential mechanism in ischemic stroke a...
Source: Cellular and Molecular Neurobiology - May 13, 2022 Category: Cytology Authors: Jiaqian Li Fangyu Dai Xuelian Kou Bin Wu Jie Xu Songbin He Source Type: research
Risk factors and predictors for venous thromboembolism in people with ischemic stroke: A systematic review
In conclusion, this systematic review informs on several potential risk factors and predictors for VTE in people with ischemic stroke. To improve risk stratification and guide development of risk prediction models, further confirmation is needed, as there were few high-quality studies on each factor.PMID:35815351 | DOI:10.1111/jth.15813
Source: Thrombosis and Haemostasis - July 11, 2022 Category: Hematology Authors: Birgitte G T øndel V ânia M Morelli John-Bjarne Hansen Sigrid K Braekkan Source Type: research
Cancer-related cryptogenic stroke involving the bilateral anterior and the posterior circulations: Diagnostic value of clinical and imaging characteristics
ConclusionCryptogenic stroke involving three circulations with cancer has unique clinical features, and these potential diagnostic indicators could help patients identify CCS earlier.
Source: Frontiers in Neurology - December 12, 2022 Category: Neurology Source Type: research
Tirofiban in the treatment of cancer-associated ischemic stroke
CONCLUSIONS: Early administration of tirofiban in the treatment of mild to moderate ischemic stroke is safe, which can reduce 24-hour and 7-day NIHSS scores and has potential value.PMID:37140310 | DOI:10.26355/eurrev_202304_32142
Source: Pharmacological Reviews - May 4, 2023 Category: Drugs & Pharmacology Authors: Z-M Zhang Z-H Lin G-L Zhu Source Type: research
